CStone Pharmaceuticals has announced that it will present new clinical advancements at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany, which is scheduled to take place from October 17-21. Key presentations will include the first-in-human Phase Ia data for the novel PD-1/VEGF/CTLA-4 trispecific antibody, CS2009, as well as the design of a global multicenter Phase Ib study for its ROR1-targeting antibody-drug conjugate $(ADC)$, CS5001. These presentations aim to showcase the latest developments from CStone's Pipeline 2.0. The company advises that the forward-looking statements made in the announcement are subject to change based on future developments.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。